Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients

Disease Management Plus Recommended Care versus Recommended Care Alone for Ambulatory COPD Patients

Am J Respir Crit Care Med.

Kalter-Leibovici O, Benderly M, Freedman LS, Kaufman G, Molcho Falkenberg Luft T, Murad H, Olmer L, Gluch M, Segev D, Gilad A, Elkrinawi S, Cukierman-Yaffe T, Chen B, Jacobson O, Key C, Shani M, Fink G

doi: 10.1164/rccm.

RECOMMENDED

COPD

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

J Am Coll Cardiol.

Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL

doi: 10.1016/j.jacc.2018.06.051.

COPD

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

Heart.

Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE; SUMMIT Investigators

doi: 10.1136/heartjnl-2016-310897.

RECOMMENDED

COPD

Predicting COPD 1-year mortality using prognostic predictors routinely measured in primary care

BMC Med.

Bloom CI, Ricciardi F, Smeeth L, Stone P, Quint JK

doi: 10.1186/s12916-019-1310-0.

RECOMMENDED

COPD

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial

JAMA.

Wise RA, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C, Gil EG

doi: 10.1001/jama.2019.4973.

COMMENTED

Effects of the "Living well with COPD" intervention in primary care: a comparative study

Eur Respir J.

Steurer-Stey C, Dalla Lana K, Braun J, Ter Riet G, Puhan MA

doi: 10.1183/

COPDPneumonia

Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention

Eur J Cardiothorac Surg.

Andell P, Sjögren J, Batra G, Szummer K, Koul S

doi: 10.1093/ejcts/ezx219.

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

Lancet.

Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators

doi: 10.1016/

Chest pain and shortness of breath in cardiovascular disease: a prospective cohort study in UK primary care

BMJ Open.

Barnett LA, Prior JA, Kadam UT, Jordan KP

doi: 10.1136/bmjopen-

Pneumology

Accelerated FEV₁ decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients

Related content

Disease Management Plus Recommended Care versus Recommended Care Alone for Ambulatory COPD Patients

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

Predicting COPD 1-year mortality using prognostic predictors routinely measured in primary care

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial

Effects of the "Living well with COPD" intervention in primary care: a comparative study

Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

Chest pain and shortness of breath in cardiovascular disease: a prospective cohort study in UK primary care